SANGAMO THERAPEUTICS, INCSGMOEarnings & Financial Report
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
SGMO Q3 2025 Key Financial Metrics
Revenue
$581.0K
Gross Profit
N/A
Operating Profit
$-35.6M
Net Profit
$-34.9M
Gross Margin
N/A
Operating Margin
-6119.3%
Net Margin
-6012.0%
YoY Growth
-98.8%
EPS
$-0.11
Financial Flow
SANGAMO THERAPEUTICS, INC Q3 2025 Financial Summary
SANGAMO THERAPEUTICS, INC reported revenue of $581.0K for Q3 2025, with a net profit of $-34.9M (-6012.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $581.0K |
|---|---|
| Net Profit | $-34.9M |
| Gross Margin | N/A |
| Operating Margin | -6119.3% |
| Report Period | Q3 2025 |
SANGAMO THERAPEUTICS, INC Annual Revenue by Year
SANGAMO THERAPEUTICS, INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $57.8M).
| Year | Annual Revenue |
|---|---|
| 2024 | $57.8M |
| 2023 | $176.2M |
| 2022 | $111.3M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $481000 | $356000 | $49.4M | $7.6M | $6.4M | $18.3M | $581000 |
| YoY Growth | -92.5% | -99.7% | -94.8% | 425.8% | 269.8% | 1238.3% | 5042.1% | -98.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $165.3M | $129.0M | $93.0M | $111.3M | $101.6M | $86.2M | $97.6M | $88.6M |
| Liabilities | $82.4M | $72.3M | $69.3M | $72.1M | $78.9M | $81.3M | $78.0M | $82.4M |
| Equity | $82.9M | $56.7M | $23.7M | $39.1M | $22.8M | $4.9M | $19.6M | $6.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-50.5M | $-48.7M | $-26.9M | $11.8M | $-3.4M | $-26.1M | $-18.2M | $-28.5M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M